MELBOURNE, Australia and
SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity
Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the
Company"), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative conditions, today
announced that David Stamler, M.D.,
Chief Executive Officer will participate in two upcoming virtual
investor events:
MST Financial Lifesciences & Biotech Fourm
Wednesday,
November 24th at 5:20 p.m.
PST (U.S.) / Thursday, November
25th at 12.20 pm
AEST
A link to the live and recorded webcast will be available on the
Alterity website.
Benchmark Company Discovery One-on-One Investor
Conference
Thursday, December
2nd (U.S.) / Friday,
December 3rd (Australia)
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company
dedicated to creating an alternate future for people
living with neurodegenerative diseases. The Company's lead
asset, ATH434, has the potential to treat various Parkinsonian
disorders. Alterity also has a broad drug discovery platform
generating patentable chemical compounds to intercede in disease
processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further
information please visit the Company's web site at
www.alteritytherapeutics.com.
Authorisation & Additional information
This
announcement was authorized by David
Stamler, CEO of Alterity Therapeutics Limited.
Contact: Investor Relations
Australia
|
US
|
Rebecca
Wilson
|
Remy
Bernarda
|
E:
WE-AUAlterity@we-worldwide.com
|
remy.bernarda@iradvisory.com
|
Tp: +61 417 382
391
|
Tp: +1 (415)
203-6386
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-two-upcoming-investor-conferences-301429828.html
SOURCE Alterity Therapeutics Limited